Peter Kertes
VANCOUVER, British Columbia — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration showed statistically significant improvements in best corrected visual acuity at 12 months compared with a monthly dosing regimen, according to a speaker here.
“Treat-and-extend induces significantly higher visual acuity improvement at 12 months compared to monthly administration and comparable improvement at 24 months, but with fewer visits and fewer injections,” Peter Kertes, MD, FRCS(C), said at the American
Uncategorized